Nexalin Technology, Inc. (NASDAQ:NXL – Free Report) – Analysts at Maxim Group issued their Q3 2026 EPS estimates for shares of Nexalin Technology in a research note issued to investors on Tuesday, September 29th. Maxim Group analyst A. Vendetti expects that the company will earn ($2.70) per share for the quarter. Maxim Group also issued estimates for Nexalin Technology’s Q4 2026 earnings at ($2.70) EPS, FY2026 earnings at ($11.40) EPS and FY2027 earnings at ($9.30) EPS.
Nexalin Technology (NASDAQ:NXL – Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($3.00) by $2.89. Nexalin Technology had a negative return on equity of 278.24% and a negative net margin of 4,141.94%.The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.09 million.
Nexalin Technology Trading Up 76.4%
Shares of NASDAQ NXL opened at $7.55 on Friday. The firm has a market capitalization of $5.51 million, a P/E ratio of -0.52 and a beta of 4.09. Nexalin Technology has a 1-year low of $4.00 and a 1-year high of $60.00. The firm’s 50-day moving average price is $7.81 and its 200-day moving average price is $10.72.
Institutional Trading of Nexalin Technology
An institutional investor recently bought a new position in Nexalin Technology stock. PEAK6 LLC acquired a new stake in shares of Nexalin Technology, Inc. (NASDAQ:NXL – Free Report) during the second quarter, according to its most recent filing with the SEC. The fund acquired 240,210 shares of the company’s stock, valued at approximately $79,000. PEAK6 LLC owned 1.09% of Nexalin Technology as of its most recent filing with the SEC. 0.65% of the stock is currently owned by institutional investors.
Trending Headlines about Nexalin Technology
Here are the key news stories impacting Nexalin Technology this week:
- Positive Sentiment: South American distribution and manufacturing agreement: Nexalin signed an exclusive agreement covering Brazil and six additional South American countries. The initial program calls for commercialization of 100 ANVISA-approved Nexalin Sync™ devices across a region representing more than 300 million people. The arrangement includes structured pricing and provisions that could support larger government and private-sector transactions, strengthening the company’s transition toward commercial revenue generation. Nexalin South America distribution and manufacturing agreement
- Positive Sentiment: Nasdaq compliance restored: Nexalin received confirmation that it had regained compliance with Nasdaq requirements, temporarily reducing the immediate risk of delisting and improving the company’s ability to maintain its market listing. Nexalin regains Nasdaq compliance
- Neutral Sentiment: Repeated trading halts highlight volatility: NXL trading was temporarily paused several times under Nasdaq’s Limit Up-Limit Down mechanism on October 1. These halts indicate unusually sharp price movements and elevated trading risk, but do not by themselves signal a change in the company’s fundamentals.
- Negative Sentiment: Analyst estimates remain deeply negative: Maxim Group projects losses of $2.70 per share for both the third and fourth quarters of 2026, a $11.40-per-share loss for fiscal 2026 and a $9.30-per-share loss for fiscal 2027. The forecasts underscore that the company remains unprofitable and that the new distribution agreement has not yet translated into demonstrated earnings.
- Negative Sentiment: Financial profile remains fragile: Nexalin’s latest reported quarter included minimal revenue, negative earnings and a sharply negative net margin. With a small market capitalization and a beta of 4.09, NXL remains highly speculative; ongoing Nasdaq listing risks could also return if the company fails to sustain compliance.
About Nexalin Technology
Nexalin Technology, Inc is a medical technology company focused on developing noninvasive neurostimulation devices designed to support brain health. Its technology uses cranial electrotherapy stimulation to deliver low-level electrical signals through electrodes placed on the head, with the aim of influencing brain activity without surgery or implanted hardware.
The company’s product portfolio includes the Nexalin Gen-2 and Gen-3 devices, which are designed for use in clinical and other supervised settings.
Read More
- Five stocks we like better than Nexalin Technology
- Everyone in AI Is Quietly Copying Palantir’s Playbook
- Advanced Micro Devices Is Spending $8.2 Billion to Learn What AI Needs Next
- JPMorgan Bets on Genius Sports as the Market Loses Patience
- Apple’s $5.7 Billion Patent Verdict Raises a Bigger Royalty Question
Receive News & Ratings for Nexalin Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexalin Technology and related companies with MarketBeat.com's FREE daily email newsletter.
